Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Consultation record

Submissions not accepted — page 4

The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it.

Submissions

98 documents · page 4 of 4

Table 1. Submissions with this disposition, on this page.

ReferenceConsultationRespondentPoint raised
DRAFT-RUSSIAN-REGI/010Draft synthesis: Nationally registered neuropeptides and the…Dr Perpetua Haverkamp-Diallo industryThe document should not describe uses outside the approved indication
DRAFT-SPONSOR-COND/003Draft synthesis: The consequences of a wholly sponsor-generated…Dr Matthias Wintringham industryThe document should not describe uses outside the approved indication
DRAFT-SURROGATE-OU/003Draft synthesis: Percentage weight change as a surrogate outcomeDr Wolfram Quintanilha industryThe document should not describe uses outside the approved indication
DRAFT-AMYLIN-ANALO/003Draft synthesis: Amylin analogues as monotherapy and in combinationDr Wolfram Quintanilha industryThe document should not describe uses outside the approved indication
DRAFT-AMYLIN-ANALO/008Draft synthesis: Amylin analogues as monotherapy and in combinationDr Adaeze Underhill-OkaforThe review question is drawn too broadly to be answerable
DRAFT-RECONSTITUTI/006Draft synthesis: Reconstitution practice and delivered doseDr Ivo QuintanilhaThe review question is drawn too broadly to be answerable
DRAFT-PANCREATITIS/004Draft synthesis: Acute pancreatitis with incretin-based therapiesDr Jozef Brandvold-AchterbergThe review question is drawn too broadly to be answerable
DRAFT-MITOCHONDRIA/005Draft synthesis: Mitochondria-targeted peptides in bioenergetic…Dr Ndidi Ravensworth-IlungaThe review question is drawn too broadly to be answerable

page 4 of 4

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.